Effects of metformin on high-fat diet-induced hyperlipidemic rats
Annisa Triskamalia Nurmalinda, Tri Wahyuni, Anton Bahtiar
Abstract
Annisa Triskamalia Nurmalinda, Tri Wahyuni, Anton Bahtiar
Abstract
Metformin as insulin sensitizer is now often associated with a significant decrease in plasma triglycerides, plasma total cholesterol, LDL cholesterol, and a significant increase in plasma HDL cholesterol without causing hypoglycemia. Current research aim are to determine the effects of metformin on high-fat diet-induced hyperlipidemic rats. To this end, a total of 30 Sprague-Dawley rats were divided into six groups (N = 5). Normal control was not treated, the negative group was given 0.5% CMC, the positive group used simvastatin dose of 1.8 mg/kg BW/day orally and three variation dose groups of metformin were given at a dose of 225; 450; and 900 mg/kg BW rat/day orally. Induction was carried out for 28 days and continued for 14 days treated with an administration orally. Lipid profile was measured by the colorimetric enzymatic method. As a result, all doses of metformin significantly decreased total cholesterol and LDL (p <0.05) compared to normal and negative controls. The highest dose significantly decreased triglyceride levels (p <0.05) and increased HDL levels (p <0.05) compared to normal and negative controls. Based on these results, metformin has a potential effect of antihyperlipidemic at a dose of 225 mg/kg BW rat.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Metformin as insulin sensitizer is now often associated with a significant decrease in plasma triglycerides, plasma total cholesterol, LDL cholesterol, and a significant increase in plasma HDL cholesterol without causing hypoglycemia. Current research aim are to determine the effects of metformin on high-fat diet-induced hyperlipidemic rats. To this end, a total of 30 Sprague-Dawley rats were divided into six groups (N = 5). Normal control was not treated, the negative group was given 0.5% CMC, the positive group used simvastatin dose of 1.8 mg/kg BW/day orally and three variation dose groups of metformin were given at a dose of 225; 450; and 900 mg/kg BW rat/day orally. Induction was carried out for 28 days and continued for 14 days treated with an administration orally. Lipid profile was measured by the colorimetric enzymatic method. As a result, all doses of metformin significantly decreased total cholesterol and LDL (p <0.05) compared to normal and negative controls. The highest dose significantly decreased triglyceride levels (p <0.05) and increased HDL levels (p <0.05) compared to normal and negative controls. Based on these results, metformin has a potential effect of antihyperlipidemic at a dose of 225 mg/kg BW rat.
Key concepts: Metformin, Simvastatin, Internal medicine, Endocrinology, Triglyceride, Cholesterol, Hyperlipidemia, Medicine